Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06923150

A Randomised Clinical Investigation to Assess Efficacy of Low Volume Transanal Irrigation by Qufora® IrriSedo MiniGo Versus Conservative Treatment for Low Anterior Resection Syndrome Patients

The purpose of this post-market clinical follow up study is to assess the efficacy on clinical symptoms of LARS of low volume Transanal Irrigation by MiniGo in conjunction with conservative treatment versus conservative treatment at 3 months.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Gastroenterology Colonic Diseases Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms LARS - Low Anterior Resection Syndrome Low Anterior Resection Syndrome Neoplasms Neoplasms by Site Pathologic Processes Pathological Conditions, Signs and Symptoms Postoperative Complications Rectal Cancer Rectal Diseases Rectal Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Amiens-Picardie, Amiens, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult aged from 18 years
  • Patients electively treated for rectal cancer with a low anterior resection
  • Between 3 and 18 months after the conservative colorectal surgery or 3 and 18 months after the stoma reversal if applicable
  • LARS score >= 25 (minor or major LARS) (Emmertsen and Laurberg 2012) AND LARS definition as consensus with at least one symptom that results in at least one consequence (Keane et al. 2020)
  • Adult for whom previous conservative treatments were started for at least a month
  • Mental and physical capability of the patient to handle the MiniGo by himself.
  • Check of the anastomosis (no signs of leakage or clinical relevant stenosis) and absence of local recurrence by Rectal digital examination of the anastomosis, any other exam used in the current practice
  • Patient affiliated to the health social security system

Exclusion criteria

  • Contra-indication to use TAI
  • Former use of TAI (post colo-rectal surgery)
  • Clinically relevant stenosis
  • Current metastatic disease or local recurrence
  • Ongoing chemotherapy
  • Postoperative radiotherapy for rectal cancer
  • History of diarrhoeal disease
  • Inflammatory bowel disease
  • Dementia
  • Spinal cord injury, multiple sclerosis, Parkinson's disease or other significant disease assessed to be a contributory cause to LARS symptoms.
  • Patient with cancer recurrence
  • Patient with a life expectancy < 1 year
  • Participating to another clinical trial for the treatment of LARS symptom
  • Ongoing pelvic floor rehabilitation/biofeedback
  • Pregnancy or intention to become pregnant during the trial period
  • Inability and unwillingness to give informed consent

Treatment and study plan

Primary outcomes

  1. LARS score difference

    Time frame: 3-month follow-up

    The primary endpoint is defined by the LARS score difference between inclusion and 3-month follow-up for each randomisation group.

Secondary outcomes

  1. efficacy on clinical symptom of transanal Irrigation by MiniGo in improving the LARS score at 6 weeks

    Time frame: 6-week follow-up

    LARS difference score between inclusion and 6-week follow-up will be calculated for each randomised arm using descriptive statistics and confidence intervals

  2. QoL with the EORTC QLQ-C30 EORTC QLQ-CR29

    Time frame: 3-month follow- up

    EORTC-QLQ-C30 and EORTC-QLQ-CR29 differences scores between inclusion and 3-month follow-up will be calculated for each randomised arm using descriptive statistics and confidence intervals.

    Also, statistical tests of superiority will be performed comparing EORTC-QLQ-C30 and EORTC-QLQ-CR29 differences between inclusion and 3-month follow-up between interventional arm and control arm

  3. change (reduction) of symptoms and consequences

    Time frame: 6 weeks and 12 weeks

    To assess the number of patients showing a change (reduction) of symptoms and consequences, as stated in the consensus definition at 6 and 12 weeks The number and the proportion of patients with each item of the LARS international consensus definition at 6 and 12 weeks will be calculated.

    Also, the proportion of patients who are considered as having no LARS at 6 and 12 weeks will be calculated with a confidence interval

  4. patient satisfaction

    Time frame: 6 weeks and 12 weeks

    to assess the patient satisfaction at 6 and 12 weeks, The proportion of patients satisfied by the treatment evaluated with the 5-point Likert Scale at 6 and 12 weeks will be calculated with a confidence interval.

  5. compliance of the patient to the treatmen

    Time frame: 6 weeks and 12 weeks

    to assess the compliance of the patient to the treatment at 6 and 12 weeks Compliance with the treatment during the 6 and 12 weeks of study with the number of days of MiniGo use per week will be calculated using descriptive statistics and confidence intervals

  6. incontinence anal score

    Time frame: 12 weeks

    To access the incontinence anal score at 12 weeks Wexner difference score between inclusion and 12-week follow-up will be calculated for each randomised arm using descriptive statistics and confidence intervals.

    Also, statistical tests of superiority will be performed comparing Wexner differences between inclusion and 12-week follow-up between interventional arm and control arm.

  7. reduction of defecations per day and night

    Time frame: 6 weeks and 12 weeks

    To assess the reduction of defecations per day and night The mean number of defecations per day and per night during the week before the randomisation and the week before the follow-up visit at 6 and 12 weeks will be calculated.

  8. time spent on bowel management (in the toilets room)

    Time frame: 12 weeks

    To assess the time spent on bowel management (in the toilets room) Mean times spent in the toilets room per day the week before the randomisation and the week before the follow-up visit at 12 weeks will be calculated using descriptive statistics.

  9. patient health organization and resources needed

    Time frame: 12 weeks

    To evaluate the patient health organization and resources needed at 12 weeks Data about quantity of organization and resources needed (professional activities, treatment, medical and specialize consultation, home helpers) will be presented using descriptive statistics.

  10. improving the LARS score

    Time frame: 6, 9 and 12 months

    to assess the efficacy on clinical symptom of Transanal Irrigation by MiniGo in improving the LARS score at 6, 9 and 12 months LARS difference score between inclusion and 6, 9 and 12-month follow-ups will be calculated using descriptive statistics and confidence intervals.

  11. number of patients showing a change (reduction) of symptoms and consequences

    Time frame: 6, 9 and 12 months

    To assess the number of patients showing a change (reduction) of symptoms and consequences, as stated in the consensus definition at 6, 9 and 12 months The number and the proportion of patients with each item of the LARS international consensus definition at 6, 9 and 12 months will be calculated.

    Also, the proportion of patients who are considered as having no LARS at 6, 9 and 12 months will be calculated with a confidence interval.

  12. Preference of the patient and reason for it

    Time frame: 12 month follow-up

    To assess the preference of the patient and reason for it Proportion of patients who stay on TAI treatment for TAI arm and proportion of patients from SOC arm whose tries and stay on TAI will be calculated using confidence intervals. Description of reasons will be also presented.

  13. QoL with the EORTC QLQ-C30 and EORTC QLQ-CR29 at 12 month

    Time frame: 12-month follow-up

    to assess the QoL with the EORTC QLQ-C30 and EORTC QLQ-CR29 EORTC-QLQ-C30 and EORTC-QLQ-CR29 differences scores between inclusion and 12-month follow-ups will be calculated for each randomised arm using descriptive statistics and confidence intervals.

  14. incontinence anal score at 12 months

    Time frame: 12-month follow-up

    Wexner difference score between inclusion and 12-month follow-up will be calculated for each randomised arm using descriptive statistics and confidence intervals.

    Also, statistical tests of superiority will be performed comparing Wexner differences between inclusion and 12-month follow-up between interventional arm and control arm

  15. patient health organization and resources needed at 6, 9 and 12 months

    Time frame: 6, 9 and 12 months

    Data about quantity of organization and resources needed (professional activities, treatment, medical and specialize consultation, home helpers) will be presented using descriptive statistics

Study contacts

Contact information is provided by the study sponsor or research team.

Rogini Balachandran

CONTACT

[email protected]

+ 45 42 40 06 20

Sponsors and collaborators

Lead sponsor

Qufora A/S

Industry

Collaborators

  • EVAMED

Registry information

Acronym: MINIGO

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Apr 11, 2025
Registry last updated
Apr 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.